Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAndrew NguyenCAC. Brooke Adams

Discussion

Loading...

Member takes

Overview

Observational analysis found improved survival with abatacept in high-risk patients, suggesting benefits for GVHD management.

Key Points

  • Survival rate was significantly higher in the TAP group, reaching 84.8% at one year, compared to 69.7% for TMP.
  • Acute graft versus host disease incidence was 33.3% in the TAP group, significantly lower than 51.5% for TMP.
  • TP53 mutation rates were comparable between TAP and TMP groups, noting 25.4% vs 20% respectively.
  • Cumulative incidence of transplant-related mortality was lower in TAP group; further trials are needed to confirm these findings.

Cite This Study

Nguyen et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d863https://doi.org/10.1182/blood-2025-4218
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  2. 2ABC: Highly active and entirely calcineurin and m-TOR inhibitor-free gvhd prevention regimen2025
  3. 3Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry2025
  4. 4Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation2025
  5. 5Impact of the addition of antithymocyte globulin to post‐transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post‐transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation2025 · 5 citations